Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral vector production, has formed a partnership with VectorBuilder, a vector design, optimization and manufacturing company. Univercells ...
read more
LGM Pharma announced new Analytical Services that provide analytical testing and stability services to pharmaceutical developers and manufacturers, including compounding pharmacies. The company is offering its analytical services expertise and ...
read more
NewAge Industries, the manufacturer of AdvantaPure® high purity tubing products, has expansion plans underway – again – at its corporate facility in southeastern Pennsylvania. The project will add over 3,000 sq. ft. of ISO Class 7 certified ...
read more
HERMES PHARMA, previously a division of HERMES Arzneimittel GmbH, announced a separate legal entity named HERMES PHARMA GmbH. The forward-looking change will see both HERMES PHARMA GmbH and HERMES Arzneimittel GmbH operating independently but ...
read more
AGC Biologics, a biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, ...
read more
Protagen Protein Services (PPS) announced that it will merge with GeneWerk, an Ampersand portfolio company. With the addition of GeneWerk’s unique capabilities in vector safety, characterization, and functionality analysis, PPS will complement its ...
read more
The Oracle Health Sciences' Clinical One platform has been selected by Servier to make its vision of a next-generation clinical trial management environment a reality. To start and manage clinical trials is a lengthy and regulated process that ...
read more
ICON plc announced the completion of its acquisition of PRA Health Sciences. The combined company will retain the name ICON and will bring together 38,000 employees across 47 countries, creating the world’s most advanced healthcare intelligence and ...
read more
OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization (CDMO), announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate ...
read more
4G Clinical, a cutting-edge randomization and trial supply management (RTSM) company, entered an agreement to receive a growth equity investment of over $230M from Goldman Sachs. The investment will be used to fund 4G Clinical's continued global ...
read more
Selexis SA and KBI Biopharm, announced that they have signed service agreements with Immatics N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies.
read more
Avacta Group plc announced a study that has shown the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples and, in this small study, outperformed two lateral flow antigen tests that are commercially ...
read more
Optibrium Limited, a provider of software and artificial intelligence (AI) solutions for drug discovery, announced the publication of a peer-reviewed study in Applied AI letters “Deep Imputation on Large-Scale Drug Discovery Data”.
read more
Charles River Laboratories announced that it has completed the acquisition of Vigene Biosciences, Inc. for $292.5 million. In addition to the initial purchase price, the transaction includes additional payments of up to $57.5 million, contingent on ...
read more
IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, announced that F-star Therapeutics dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.
read more